Agentix (AGTX) EBT Margin (2015 - 2021)
Agentix's (AGTX) quarterly EBT Margin came in at 19631.13% in Q3 2021, down 185.68% on a QoQ basis from 6871.69% in Q1 2017.
Agentix (AGTX) EBT Margin (2015 - 2021) Analysis & Trends
Agentix (AGTX) has 4 years of EBT Margin data on file, last reported at 19631.13% in Q3 2021.
- Quarterly EBT Margin changed N/A year-over-year to 19631.13% in Q3 2021, while the trailing twelve-month figure through Mar 2023 was 110790.73% (changed N/A YoY) and the FY2022 annual result came in at 211825.08%, changed N/A from the prior year.
- EBT Margin fell to 19631.13% in Q3 2021, from 6871.69% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 6871.69% in Q1 2017 to a low of 19631.13% in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 12.09% |
| 10 | Agentix | 801,339.00 | 801,301.00 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Aug 31, 2021 | -19,631.13% |
| Feb 28, 2017 | -6,871.69% |
| Aug 31, 2016 | -13,012.54% |
| May 31, 2016 | -1,464.73% |
| Feb 29, 2016 | 2.29% |
| Nov 30, 2015 | -2.33% |
| Aug 31, 2015 | -145.27% |
| May 31, 2015 | -137.20% |